Market revenue in 2020 | USD 588.9 million |
Market revenue in 2028 | USD 1,206.9 million |
Growth rate | 9.4% (CAGR from 2020 to 2028) |
Largest segment | Laboratory technologies |
Fastest growing segment | Online Technologies |
Historical data | 2020 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Laboratory Technologies, Online Technologies |
Key market players worldwide | Thermo Fisher Scientific Inc, Pfizer Inc, Sartorius AG, Stemcell Holdings Inc Ordinary Shares, Illumina Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Merck KGaA, Qiagen NV, Shimadzu Corp, Eurofins Scientific SE, Charles River Laboratories International Inc, Takara Bio Inc, Olympus Corp, Avantor Inc, Aurora Innovation Inc Class A, Standard BioTools Inc, Celerion, Cole-Parmer, Hartford Schroders International Stk I, Revvity Inc, Fluidigm Corporation, Polyplus-transfection, Hamilton Lane Inc Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to covid-19 vaccine development tools market will help companies and investors design strategic landscapes.
Laboratory technologies was the largest segment with a revenue share of 95.35% in 2020. Horizon Databook has segmented the Russia covid-19 vaccine development tools market based on laboratory technologies, online technologies covering the revenue growth of each sub-segment from 2020 to 2028.
Russia was the first country to approve a COVID-19 vaccine in August 2020. The vaccine was developed by Gamely National Center of Epidemiology and Microbiology in Moscow and received approval from the President.
However, other regulators, such as the U.S. FDA and EMA, found insufficient information to approve the vaccination. In November 2021, the developer announced that Sputnik V was proven effective against the new Omicron and Delta variant.
The development of the vaccine was financially supported through the Russian Direct Investment Fund (RDIF). It is a sovereign fund with a capital of USD 10 billion under management and has investors from over 15 countries.
Horizon Databook provides a detailed overview of country-level data and insights on the Russia covid-19 vaccine development tools market , including forecasts for subscribers. This country databook contains high-level insights into Russia covid-19 vaccine development tools market from 2020 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account